Journey Medical CORP (DERM) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

DERM ranks #5276 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

73 institutions disclose a position in DERM, but none treat it as a major bet — even Tang Capital Management LLC, its most concentrated holder, allocates just 0.5% of its own portfolio to it.

Jane Street Group, LLC has added to its DERM position for two straight quarters, increasing it by $2.4M to reach $2.5M today.

J. Goldman & Co LP has trimmed its DERM position for two straight quarters, cutting it by $5.2M while still holding $974.1K.

DERM is up 2.6% today, but institutions show net selling of $5.4M this quarter — a divergence between today's price move and the underlying institutional flow.

DERM reported a net loss of $6.1M over the trailing twelve months.

• Not yet profitable — net loss of $6.1M over the trailing twelve months
• Revenue grew 20.7% year over year
• Net income improved year over year, from -$8.7M to -$6.1M
• Operating cash flow was negative, using $12.4M in cash
• Current ratio of 1.79x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.97x equity — within a conventional range